Live at #AACR26: Raffaele Colombo (@raffcolo @ZymeworksInc) traces the evolution of antibody-drug conjugates and how advances in linker and payload design are driving today’s impact and enabling the next wave of ADC innovation.

Key takeaways:
• ADCs are important and effective drugs but are very complex.

• Next-generation ADCs will be multi-dimensional:
• novel targets, including multi-targets
• novel payloads, including multi-payloads, optimized for ADCs
• novel multi-dimensional biomarkers for patient selection

• Novel linkers, aiming for truly tumor-specific linkers but we need a deeper understanding of PK/PD for ADCs.

#MoffittAACR26